C. Yang

发表

Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer

K. Yeh, A. Cheng, J. F. Lin, 2005, British Journal of Cancer.

A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2).

J. Shih, V. Miller, Yuh-Min Chen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial

J. Shih, V. Miller, Chun-Ming Tsai, 2008 .

Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL).

J. Vansteenkiste, F. Blackhall, J. Raats, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).

J. Shih, S. Ou, V. Miller, 2010 .

Pharmacoeconomic study in head and neck cancer patients: Impact of prospective DPD deficiency screening with 5-fluorouracil (5-FU) dose tailoring on toxicities-related costs.

B. Lacarelle, J. Ciccolini, S. Duflo, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

K. Yeh, A. Cheng, N. Chiang, 2015, Cancer Chemotherapy and Pharmacology.

Induction of esophageal cancers by nitenpyram (NIT) in rats.

Y. Wu, G. Wu, L. Xing, 2018, European review for medical and pharmacological sciences.

A phase II study of gefitinib as first line treatment for good performance advanced or metastatic non-small cell lung cancer in East Asian patients.

P. Yang, S. Kuo, C. Yang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.

D. Esseltine, J. Stec, G. Hortobagyi, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial.

C. Hsu, C. Yang, A. Cheng, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer

K. Yeh, A. Cheng, J. F. Lin, 2005, British Journal of Cancer.

Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer

Ym Chen, A. Cheng, P-C. Yang, 2002, British Journal of Cancer.

Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.

Ding‐Shinn Chen, R. Fine, K. Yeh, 1998, Hepato-gastroenterology.

Polyprenoic acid in hepatocellular carcinoma.

A. Cheng, C. Yang, 1996, The New England journal of medicine.

A phase I dose-escalation study of the polo-like kinase 1 inhibitor volasertib (BI 6727) with two different dosing schedules in patients with advanced solid malignancies.

T. Taube, W. Su, H. Fritsch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical efficacy of palbociclib-based therapy in women with HR+/HER2- metastatic breast cancer in the real-world setting for Chinese women: a comparison with the IRIS study.

Q. Qu, C. Yang, M. Jiang, 2021, European review for medical and pharmacological sciences.

Phase I study of liposome encapsulated irinotecan (PEP02) in advanced solid tumor patients

A. Cheng, Jang-Yang Chang, H. Shiah, 2008 .

A phase I study of HMPL-689, a selective oral phosphoinositide 3-kinase-delta inhibitor, in patients with relapsed or refractory lymphoma

N. Ghosh, J. Kauh, Jonathon B. Cohen, 2019, Annals of Oncology.

Efficacy of pemetrexed-cisplatin (PC) in East Asian patients (pts): Subgroup analysis of a phase III study comparing PC versus gemcitabine-cisplatin (GC) in first-line treatment of advanced non-small cell lung cancer (NSCLC).

M. Orlando, C. Yang, L. Simms, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.